Alexander Kutikov

List of Publications by Year
in descending order

207 papers	11,063 citations	41344 49 h-index	33894 99 g-index
211 all docs	211 docs citations	211 times ranked	9539 citing authors

#	Article	IF	Citations
1	The R.E.N.A.L. Nephrometry Score: A Comprehensive Standardized System for Quantitating Renal Tumor Size, Location and Depth. Journal of Urology, 2009, 182, 844-853.	0.4	1,886
2	Understanding Pathologic Variants of Renal Cell Carcinoma: Distilling Therapeutic Opportunities from Biologic Complexity. European Urology, 2015, 67, 85-97.	1.9	403
3	Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. European Urology, 2015, 68, 959-967.	1.9	395
4	A War on Two Fronts: Cancer Care in the Time of COVID-19. Annals of Internal Medicine, 2020, 172, 756-758.	3.9	340
5	Small renal masses progressing to metastases under active surveillance. Cancer, 2012, 118, 997-1006.	4.1	332
6	Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies. Molecular Cancer Therapeutics, 2018, 17, 1355-1364.	4.1	280
7	Renal Ischemia and Function After Partial Nephrectomy: A Collaborative Review of the Literature. European Urology, 2015, 68, 61-74.	1.9	274
8	Incidence of benign pathologic findings at partial nephrectomy for solitary renal mass presumed to be renal cell carcinoma on preoperative imaging. Urology, 2006, 68, 737-740.	1.0	271
9	Evaluating Overall Survival and Competing Risks of Death in Patients With Localized Renal Cell Carcinoma Using a Comprehensive Nomogram. Journal of Clinical Oncology, 2010, 28, 311-317.	1.6	265
10	Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Is Safe, Effective, and Efficient Neoadjuvant Treatment for Muscle-Invasive Bladder Cancer: Results of a Multicenter Phase II Study With Molecular Correlates of Response and Toxicity. Journal of Clinical Oncology, 2014, 32, 1895-1901.	1.6	241
11	Anatomic Features of Enhancing Renal Masses Predict Malignant and High-Grade Pathology: A Preoperative Nomogram Using the RENAL Nephrometry Score. European Urology, 2011, 60, 241-248.	1.9	233
12	Objective Measures of Renal Mass Anatomic Complexity Predict Rates of Major Complications Following Partial Nephrectomy. European Urology, 2011, 60, 724-730.	1.9	232
13	A Literature Review of Renal Surgical Anatomy and Surgical Strategies for Partial Nephrectomy. European Urology, 2015, 68, 980-992.	1.9	206
14	Utility of the R.E.N.A.L. Nephrometry Scoring System in Objectifying Treatment Decision-making of the Enhancing Renal Mass. Urology, 2011, 78, 1089-1094.	1.0	148
15	Zinc and zinc transporters in prostate carcinogenesis. Nature Reviews Urology, 2013, 10, 219-226.	3.8	140
16	Robot-assisted Partial Nephrectomy: A Large Single-institutional Experience. Urology, 2010, 75, 1328-1334.	1.0	136
17	Robot Assisted Pyeloplasty in the Infantâ€"Lessons Learned. Journal of Urology, 2006, 176, 2237-2240.	0.4	132
18	Indications, Techniques, Outcomes, and Limitations for Minimally Ischemic and Off-clamp Partial Nephrectomy: A Systematic Review of the Literature. European Urology, 2015, 68, 632-640.	1.9	127

#	Article	IF	Citations
19	Initial Experience With Laparoscopic Transvesical Ureteral Reimplantation at the Childrenâ€™s Hospital of Philadelphia. Journal of Urology, 2006, 176, 2222-2226.	0.4	126
20	Laparoscopic Pyeloplasty in the Infant Younger Than 6 Monthsâ€"Is it Technically Possible?. Journal of Urology, 2006, 175, 1477-1479.	0.4	115
21	Outcomes of Robot-assisted Partial Nephrectomy for Clinical T2 Renal Tumors: A Multicenter Analysis (ROSULA Collaborative Group). European Urology, 2018, 74, 226-232.	1.9	109
22	Competing Risks of Death in Patients with Localized Renal Cell Carcinoma: A Comorbidity Based Model. Journal of Urology, 2012, 188, 2077-2083.	0.4	108
23	Active Surveillance for Localized Renal Masses: Tumor Growth, Delayed Intervention Rates, and >5-yr Clinical Outcomes. European Urology, 2018, 74, 157-164.	1.9	106
24	Partial nephrectomy for renal masses â‰¥7â€ƒcm: technical, oncological and functional outcomes. BJU International, 2012, 109, 1450-1456.	2.5	102
25	Collaborative Review of Risk Benefit Trade-offs Between Partial and Radical Nephrectomy in the Management of Anatomically Complex Renal Masses. European Urology, 2017, 72, 64-75.	1.9	91
26	Standardized Reporting of Resection Technique During Nephron-sparing Surgery: The Surfaceâ€"Intermediateâ€"Base Margin Score. European Urology, 2014, 66, 803-805.	1.9	86
27	Role of Active Surveillance for Localized Small Renal Masses. European Urology Oncology, 2018, 1, 177-187.	5.4	85
28	Perioperative Outcomes of Robotic and Open Partial Nephrectomy for Moderately and Highly Complex Renal Lesions. Journal of Urology, 2012, 187, 2000-2004.	0.4	83
29	Renal Mass Biopsy: Always, Sometimes, or Never?. European Urology, 2016, 70, 403-406.	1.9	80
30	Testicular Compartment Syndrome: A New Approach to Conceptualizing and Managing Testicular Torsion. Urology, 2008, 72, 786-789.	1.0	77
31	Modulation of Akt/mTOR Signaling Overcomes Sunitinib Resistance in Renal and Prostate Cancer Cells. Molecular Cancer Therapeutics, 2012, 11, 1510-1517.	4.1	75
32	Coâ€administration of piperine and docetaxel results in improved antiâ€tumor efficacy via inhibition of CYP3A4 activity. Prostate, 2012, 72, 661-667.	2.3	74
33	European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media. European Urology, 2014, 66, 628-632.	1.9	72
34	Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladderâ€preservation therapy for muscleâ€invasive bladder cancer. Cancer, 2017, 123, 4337-4345.	4.1	72
35	Piperlongumine inhibits NFâ€ÎºB activity and attenuates aggressive growth characteristics of prostate cancer cells. Prostate, 2014, 74, 177-186.	2.3	70
36	Growth Kinetics and Short-Term Outcomes of cT1b and cT2 Renal Masses under Active Surveillance. Journal of Urology, 2014, 192, 659-664.	0.4	70

#	Article	IF	Citations
37	Prevalence of Baseline Chronic Kidney Disease in Patients Presenting With Solid Renal Tumors. Urology, 2011, 77, 781-785.	1.0	67
38	Von Hippel-Lindau Disease: Current Challenges and Future Prospects . OncoTargets and Therapy, 2020, Volume 13, 5669-5690.	2.0	66
39	Ischemia Techniques in Nephron-sparing Surgery: A Systematic Review and Meta-Analysis of Surgical, Oncological, and Functional Outcomes. European Urology, 2019, 75, 477-491.	1.9	65
40	Residual Parenchymal Volume, Not Warm Ischemia Time, Predicts Ultimate Renal Functional Outcomes in Patients Undergoing Partial Nephrectomy. Urology, 2015, 86, 300-306.	1.0	64
41	Baseline Renal Function Status Limits Patient Eligibility to Receive Perioperative Chemotherapy for Invasive Bladder Cancer and Is Minimally Affected by Radical Cystectomy. Urology, 2011, 77, 160-165.	1.0	63
42	Assessing the Burden of Complications After Surgery for Clinically Localized Kidney Cancer by Age and Comorbidity Status. Urology, 2014, 83, 843-850.	1.0	63
43	Predictive Value of Nephrometry Scores in Nephron-sparing Surgery: A Systematic Review and Meta-analysis. European Urology Focus, 2020, 6, 490-504.	3.1	63
44	Impact of Resection Technique on Perioperative Outcomes and Surgical Margins after Partial Nephrectomy for Localized Renal Masses: A Prospective Multicenter Study. Journal of Urology, 2020, 203, 496-504.	0.4	61
45	Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. BJU International, 2010, 106, 218-223.	2.5	60
46	Piperlongumine induces rapid depletion of the androgen receptor in human prostate cancer cells. Prostate, 2013, 73, 23-30.	2.3	58
47	High rates of advanced disease, complications, and decline of renal function after radical nephroureterectomy. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 47.e9-47.e14.	1.6	55
48	Assessing Performance Trends in Laparoscopic Nephrectomy and Nephron-sparing Surgery for Localized Renal Tumors. Urology, 2012, 80, 286-292.	1.0	53
49	Online Professionalismâ€”2018 Update of European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media. European Urology, 2018, 74, 644-650.	1.9	53
50	Defects in DNA Repair Genes Confer Improved Long-term Survival after Cisplatin-based Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. European Urology Oncology, 2020, 3, 544-547.	5.4	52
51	Coexisting Hybrid Malignancy in a Solitary Sporadic Solid Benign Renal Mass: Implications for Treating Patients Following Renal Biopsy. Journal of Urology, 2014, 191, 296-300.	0.4	49
52	Collaborative Review: Factors Influencing Treatment Decisions for Patients with a Localized Solid Renal Mass. European Urology, 2021, 80, 575-588.	1.9	48
53	Assessing the relative influence of hospital and surgeon volume on shortâ€term mortality after radical cystectomy. BJU International, 2017, 120, 239-245.	2.5	47
54	Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy. BJU International, 2011, 107, 58-62.	2.5	46

#	Article	IF	Citations
55	Does Partial Nephrectomy Result in a Durable Overall Survival Benefit in the Medicare Population?. Journal of Urology, 2012, 188, 2089-2094.	0.4	46
56	Nephronâ€sparing management vs radical nephroureterectomy for lowâ€or moderateâ€grade, lowâ€stage upper tract urothelial carcinoma. BJU International, 2014, 114, 216-220.	2.5	46
57	Novel Imaging Methods for Renal Mass Characterization: A Collaborative Review. European Urology, 2022, 81, 476-488.	1.9	44
58	Laparoscopic and Robotic Complex Upper-Tract Reconstruction in Children with a Duplex Collecting System. Journal of Endourology, 2007, 21, 621-624.	2.1	43
59	Robotic partial nephrectomy vs minimally invasive radical nephrectomy for clinical T2a renal mass: a propensity scoreâ€matched comparison from the ROSULA (Robotic Surgery for Large Renal Mass) Collaborative Group. BJU International, 2020, 126, 114-123.	2.5	42
60	Familiarity and Self-Reported Compliance with American Urological Association Best Practice Recommendations for Use of Thromboembolic Prophylaxis among American Urological Association Members. Journal of Urology, 2013, 190, 992-998.	0.4	41
61	Treatment Facility Volume and Survival in Patients with Metastatic Renal Cell Carcinoma: A Registry-based Analysis. European Urology, 2018, 74, 387-393.	1.9	41
62	Prostate Bed Motion During Intensity-Modulated Radiotherapy Treatment. International Journal of Radiation Oncology Biology Physics, 2012, 84, 130-136.	0.8	40
63	Social Media Offers Unprecedented Opportunities for Vibrant Exchange of Professional Ideas Across Continents. European Urology, 2014, 66, 118-119.	1.9	40
64	The metastatic potential of renal tumors: Influence of histologic subtypes on definition of small renal masses, risk stratification, and future active surveillance protocols. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 153.e15-153.e20.	1.6	39
65	Focal therapy for kidney cancer: a systematic review. Current Opinion in Urology, 2009, 19, 148-153.	1.8	38
66	Trends in regionalization of radical cystectomy in three large northeastern states from 1996 to 2009. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1663-1669.	1.6	38
67	Urology Tag Ontology Project: Standardizing Social Media Communication Descriptors. European Urology, 2016, 69, 183-185.	1.9	38
68	RENAL Nephrometry Scoring System: The Radiologistâ€™s Perspective. American Journal of Roentgenology, 2012, 199, W355-W359.	2.2	37
69	Piperlongumine and its analogs down-regulate expression of c-Met in renal cell carcinoma. Cancer Biology and Therapy, 2015, 16, 743-749.	3.4	37
70	Partial nephrectomy is not associated with an overall survival advantage over radical nephrectomy in elderly patients with stage Ibâ€ renal masses: An analysis of the national cancer data base. Cancer, 2018, 124, 3839-3848.	4.1	37
71	Enucleation of renal cell carcinoma with ablation of the tumour base. BJU International, 2008, 102, 688-691.	2.5	36
72	Lymphopenia is an independent predictor of inferior outcome in papillary renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 388.e19-388.e25.	1.6	36

#	Article	IF	Citations
73	Understanding Treatment Disconnect and Mortality Trends in Renal Cell Carcinoma Using Tumor Registry Data. Medical Care, 2017, 55, 398-404.	2.4	36
74	Robotic versus laparoscopic radical nephrectomy: a large multi-institutional analysis (ROSULA) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 702	2.2	36
75	Thermal ablation of the small renal mass: Case selection using the R.E.N.A.L.-Nephrometry Score. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1292-1297.	1.6	35
76	The convergent roles of NF-ÎºB and ER stress in sunitinib-mediated expression of pro-tumorigenic cytokines and refractory phenotype in renal cell carcinoma. Cell Death and Disease, 2018, 9, 374.	6.3	35
77	Focal ablation therapy for renal cancer in the era of active surveillance and minimally invasive partial nephrectomy. Nature Reviews Urology, 2017, 14, 669-682.	3.8	34
78	Percutaneous vs surgical cryoablation of the small renal mass: is efficacy compromised?. BJU International, 2011, 107, 1376-1380.	2.5	33
79	Care Transitions between Hospitals are Associated with Treatment Delay for Patients with Muscle Invasive Bladder Cancer. Journal of Urology, 2014, 192, 1349-1354.	0.4	33
80	Discrimination of malignant and normal kidney tissue with short wave infrared dispersive Raman spectroscopy. Journal of Biophotonics, 2018, 11, e201700188.	2.3	33
81	Differential Use of Partial Nephrectomy for Intermediate and High Complexity Tumors May Explain Variability in Reported Utilization Rates. Journal of Urology, 2013, 189, 2047-2053.	0.4	32
82	Renal Pelvic Anatomy Is Associated with Incidence, Grade, and Need for Intervention for Urine Leak Following Partial Nephrectomy. European Urology, 2014, 66, 949-955.	1.9	32
83	Temporal Trends and Factors Associated with Systemic Therapy after Cytoreductive Nephrectomy: An Analysis of the National Cancer Database. Journal of Urology, 2015, 193, 1108-1113.	0.4	32
84	Advanced small cell carcinoma of the bladder: clinical characteristics, treatment patterns and outcomes in 960 patients and comparison with urothelial carcinoma. Cancer Medicine, 2016, 5, 192-199.	2.8	32
85	Active Surveillance for Small Renal Masses: When Less is More. European Urology Focus, 2016, 2, 660-668.	3.1	31
86	Trends in Regionalization of Adrenalectomy to Higher Volume Surgical Centers. Journal of Urology, 2012, 188, 377-383.	0.4	30
87	Pathological Concordance and Surgical Outcomes of Sporadic Synchronous Unilateral Multifocal Renal Masses Treated with Partial Nephrectomy. Journal of Urology, 2013, 189, 43-47.	0.4	29
88	Hypoalbuminaemia is associated with mortality in patients undergoing cytoreductive nephrectomy. BJU International, 2015, 116, 351-357.	2.5	29
89	Disparities in Treatment of Patients With High-risk Prostate Cancer: Results From a Population-based Cohort. Urology, 2016, 95, 88-94.	1.0	29
90	Surgical Apgar Score Predicts an Increased Risk of Major Complications and Death after Renal Mass Excision. Journal of Urology, 2015, 193, 1918-1922.	0.4	28

#	Article	IF	Citations
91	Anatomic Complexity Quantitated by Nephrometry Score Is Associated With Prolonged Warm Ischemia Time During Robotic Partial Nephrectomy. Urology, 2014, 84, 340-344.	1.0	27
92	Clinical Characteristics Associated With Treatment Type for Localized Renal Tumors: Implications for Practice Pattern Assessment. Urology, 2013, 81, 269-276.	1.0	26
93	Internal Validation of the Renal Pelvic Score: A Novel Marker of Renal Pelvic Anatomy That Predicts Urine Leak After Partial Nephrectomy. Urology, 2014, 84, 351-357.	1.0	26
94	Is anatomic complexity associated with renal tumor growth kinetics under active surveillance?. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 167.e7-167.e12.	1.6	26
95	Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-Invasive Bladder Cancer: Results of a Phase 2 Trial. European Urology Oncology, 2018, 1, 54-60.	5.4	26
96	Triggers for delayed intervention in patients with small renal masses undergoing active surveillance: a systematic review. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 389-407.	3.9	26
97	Histopathological Validation of the Surface-Intermediate-Base Margin Score for Standardized Reporting of Resection Technique during Nephron Sparing Surgery. Journal of Urology, 2015, 194, 916-922.	0.4	25
98	LDL cholesterol counteracts the antitumour effect of tyrosine kinase inhibitors against renal cell carcinoma. British Journal of Cancer, 2017, 116, 1203-1207.	6.4	25
99	Prediction of significant estimated glomerular filtration rate decline after renal unit removal to aid in the clinical choice between radical and partial nephrectomy in patients with a renal mass and normal renal function. BJU International, 2019, 124, 999-1005.	2.5	25
100	Clinically localized type 1 and 2 papillary renal cell carcinomas have similar survival outcomes following surgery. World Journal of Urology, 2016, 34, 687-693.	2.2	24
101	National treatment trends among older patients with T1-localized renal cell carcinoma11Dr. Simon P. Kim is supported by a career development award from the Conquer Cancer Foundation from the American Society of Clinical Oncology.. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 113.e15-113.e21.	1.6	24
102	Effects of Increased Cross-Sectional Imaging on the Diagnosis and Prognosis of Adrenocortical Carcinoma: Analysis of the National Cancer Database. Journal of Urology, 2011, 186, 805-810.	0.4	22
103	Extended Venous Thromboembolism Prophylaxis after Radical Cystectomy: A Call for Adherence to Current Guidelines. Journal of Urology, 2018, 199, 906-914.	0.4	22
104	Routine Adrenalectomy Is Unnecessary During Surgery for Large and/or Upper Pole Renal Tumors When the Adrenal Gland Is Radiographically Normal. Journal of Urology, 2011, 185, 1198-1203.	0.4	21
105	Reversal of epigenetic silencing of AP-2alpha results in increased zinc uptake in DU-145 and LNCaP prostate cancer cells. Carcinogenesis, 2011, 32, 1773-1781.	2.8	21
106	Evaluating toxicity from definitive radiation therapy for prostate cancer in men with inflammatory bowel disease: Patient selection and dosimetric parameters with modern treatment techniques. Practical Radiation Oncology, 2015, 5, e215-e222.	2.1	21
107	Papillary Renal Neoplasm With Reverse Polarity Is Often Cystic. American Journal of Surgical Pathology, 2022, 46, 336-343.	3.7	20
108	Is radical nephrectomy a legitimate therapeutic option in patients with renal masses amenable to nephronâ€sparing surgery?. BJU International, 2015, 115, 357-363.	2.5	19

#	Article	IF	Citations
109	Variation in performance of candidate surgical quality measures for muscleâ€invasive bladder cancer by hospital type. BJU International, 2015, 115, 230-237.	2.5	18
110	Small-Cell Carcinoma of the Bladder: 20-Year Single-Institution Retrospective Review. Clinical Genitourinary Cancer, 2017, 15, e337-e343.	1.9	18
111	Assessment of volume preservation performed before or after partial nephrectomy accurately predicts postoperative renal function: Results from a prospective multicenter study. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 33-39.	1.6	18
112	Comparison of radiographical imaging modalities for measuring the diameter of renal masses: is there a sizeable difference?. BJU International, 2011, 108, E232-E236.	2.5	17
113	Partial Versus Radical Nephrectomy: Balancing Nephrons and Perioperative Risk. European Urology, 2013, 64, 607-609.	1.9	17
114	External Validation of Contact Surface Area as a Predictor of Postoperative Renal Function in Patients Undergoing Partial Nephrectomy. Journal of Urology, 2018, 199, 649-654.	0.4	17
115	Renal Hilar Lesions: Biological Implications for Complex Partial Nephrectomy. Urology, 2019, 123, 174-180.	1.0	17
116	Are all multi-targeted tyrosine kinase inhibitors created equal? An in vitro study of sunitinib and pazopanib in renal cell carcinoma cell lines. Canadian Journal of Urology, 2011, 18, 5819-25.	0.0	17
117	Contemporary practice patterns and survival outcomes for locally advanced urethral malignancies: A National Cancer Database Analysis. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 670.e15-670.e21.	1.6	16
118	Should Partial Nephrectomy Be Offered to All Patients Whenever Technically Feasible?. European Urology, 2012, 61, 732-734.	1.9	15
119	Association of tumor size with metastatic potential and survival in patients with adrenocortical carcinoma: an analysis of the National Cancer Database. Canadian Journal of Urology, 2013, 20, 6915-21.	0.0	15
120	Renal Masses Herniating Into the Hilum: Technical Considerations of the â€œBall-valve Phenomenonâ€• During Nephron-sparing Surgery. Urology, 2010, 75, 707-710.	1.0	14
121	Docetaxelâ€mediated apoptosis in myeloid progenitor TFâ€1 cells is mitigated by zinc: Potential implication for prostate cancer therapy. Prostate, 2011, 71, 1413-1419.	2.3	14
122	Update on Renal Mass Biopsy. Current Urology Reports, 2017, 18, 28.	2.2	14
123	Perioperative Outcomes Following Partial Nephrectomy Performed on Patients Remaining on Antiplatelet Therapy. Journal of Urology, 2017, 197, 31-36.	0.4	14
124	Assessment of Prostate Cancer Treatment Among Black and White Patients During the COVID-19 Pandemic. JAMA Oncology, 2021, 7, 1467.	7.1	14
125	Academic Ranking Score: A Publication-Based Reproducible Metric of Thought Leadership in Urology. European Urology, 2012, 61, 435-439.	1.9	13
126	Patients with anatomically â€œsimpleâ€•renal masses are more likely to be placed on active surveillance than those with anatomically â€œcomplexâ€•lesions. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1267-1271.	1.6	13

#	Article	IF	Citations
127	Focal Therapy for Treatment of the Small Renal Mass: Dealer's Choice or a Therapeutic Gamble?. European Urology, 2015, 67, 260-261.	1.9	13
128	Association of race and margin status among patients undergoing robotic partial nephrectomy for T1 renal cell carcinoma: Results from a population-based cohort. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 662.e17-662.e21.	1.6	13
129	Implantation of electromagnetic transponders following radical prostatectomy for delivery of IMRT. Canadian Journal of Urology, 2010, 17, 5365-9.	0.0	13
130	Is Extended Pharmacologic Venous Thromboembolism Prophylaxis Uniformly Safe After Radical Cystectomy?. Urology, 2014, 84, 1152-1156.	1.0	12
131	Small renal mass management in the elderly and the calibration of risk. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 197-200.	1.6	12
132	Effect of delayed resection after initial surveillance and tumor growth rate on final surgical pathology in patients with small renal masses (SRMs). Urologic Oncology: Seminars and Original Investigations, 2016, 34, 486.e9-486.e15.	1.6	12
133	Controversies in management of the bladder cuff at nephroureterectomy. Translational Andrology and Urology, 2020, 9, 1868-1880.	1.4	12
134	Association of Surgical Delay and Overall Survival in Patients With T2 Renal Masses: Implications for Critical Clinical Decision-making During the COVID-19 Pandemic. Urology, 2021, 147, 50-56.	1.0	12
135	Impact of surgical approach and resection technique on the risk of Trifecta Failure after partial nephrectomy for highly complex renal masses. European Journal of Surgical Oncology, 2022, 48, 687-693.	1.0	12
136	Current Role of Renal Biopsy in Urologic Practice. Urologic Clinics of North America, 2017, 44, 203-211.	1.8	11
137	Treatment Facility Volume and Survival in Patients with Advanced Prostate Cancer. European Urology Oncology, 2020, 3, 104-111.	5.4	11
138	Cystoscopy and Systematic Bladder Tissue Sampling in Predicting pT0 Bladder Cancer: A Prospective Trial. Journal of Urology, 2021, 205, 1605-1611.	0.4	11
139	Retrospective Comparison of Cardiovascular Risk in Preselected Patients Undergoing Kidney Cancer Surgery: Reflection of Reality or Simply What We Want to Hear?. European Urology, 2015, 67, 690-691.	1.9	10
140	Trends in Regionalization of Care and Mortality For Patients Treated With Radical Cystectomy. Medical Care, 2019, 57, 728-733.	2.4	10
141	Kidney cancer management 3.0: can artificial intelligence make us better?. Current Opinion in Urology, 2021, 31, 409-415.	1.8	10
142	Role of tumor location in selecting patients for percutaneous versus surgical cryoablation of renal masses. Canadian Journal of Urology, 2012, 19, 6417-22.	0.0	10
143	Ischemia Time Has Little Influence on Renal Function Following Partial Nephrectomy: Is It Time for Urology to Stop the Tick-Tock Dance?. European Urology, 2022, 81, 501-502.	1.9	10
144	The Role of Minimally Invasive Surgery in Multifocal Renal Cell Carcinoma. Current Urology Reports, 2012, 13, 202-210.	2.2	9

#	Article	IF	Citations
145	Effect of Obesity and Overweight Status on Complications and Survival After Minimally Invasive Kidney Surgery in Patients with Clinical T₂₋₄ Renal Masses. Journal of Endourology, 2020, 34, 289-297.	2.1	9
146	Impact of Trifecta definition on rates and predictors of "successful" robotic partial nephrectomy for localized renal masses: results from the Surface-Intermediate-Base Margin Score International Consortium. Minerva Urology and Nephrology, 2022, 74, 186-193.	2.5	9
147	Delayed proximal ureteric stricture formation after complex partial nephrectomy. BJU International, 2012, 109, 539-543.	2.5	8
148	Contemporary Trends in the Utilization of Radiotherapy in Patients With Renal Cell Carcinoma. Urology, 2015, 86, 1165-1173.	1.0	8
149	Perceptions of Prostate MRI and Fusion Biopsy of Radiation Oncologists and Urologists for Patients Diagnosed with Prostate Cancer: Results from a National Survey. European Urology Focus, 2020, 6, 273-279.	3.1	8
150	Communication Between the Ureter and an Aortic Aneurysm Sac After an Abdominal Aortic Aneurysm Repair. Urology, 2008, 71, 351.e7-351.e8.	1.0	7
151	Coupling of Prostate and Thyroid Cancer Diagnoses in the United States. Annals of Surgical Oncology, 2015, 22, 1043-1049.	1.5	7
152	Understanding Chronic Kidney Disease of Surgical Versus Medical Origin: The Missing Link to the Partial Versus Radical Nephrectomy Debate?. European Urology, 2015, 68, 1004-1006.	1.9	7
153	Pheochromocytoma in Urologic Practice. European Urology Focus, 2016, 1, 231-240.	3.1	7
154	Role of minimally invasive partial nephrectomy in the management of renal mass. Translational Andrology and Urology, 2020, 9, 3140-3148.	1.4	7
155	Biochemical and clinical experience with real-time intraoperatively planned permanent prostate brachytherapy. Brachytherapy, 2012, 11, 209-213.	0.5	6
156	Surveillance of Small Renal Masses in Young Patients: A Viable Option in the Appropriate Candidate. European Urology Focus, 2016, 2, 567-568.	3.1	6
157	Needle Tract Seeding Following Renal Tumor Biopsy: Scarcely a Concern or a Concern to Scare?. European Urology, 2019, 75, 868-870.	1.9	6
158	Clinical Approach to the Prostate: An Update. Radiologic Clinics of North America, 2006, 44, 649-663.	1.8	5
159	Comparison of prostate cancer diagnosis in patients receiving unrelated urological and nonâ€urological cancer care. BJU International, 2013, 112, 161-168.	2.5	5
160	Some Renal Masses Did Not â€œRead the Bookâ€: A Case of a High Grade Hybrid Renal Tumor Masquerading as a Renal Cyst on Non-contrast Imaging. Urology Case Reports, 2015, 3, 219-220.	0.3	5
161	Defining Novel and Practical Metrics to Assess the Deliverables of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy. Journal of Urology, 2018, 199, 969-975.	0.4	5
162	Functional Parenchymal Volume-based Spectrum Score Is Able to Quantify Ischemic Injury After Partial Nephrectomy. Urology, 2018, 120, 150-155.	1.0	5

#	Article	IF	Citations
163	Enhancing Renal Tumors in Patients with Prior Normal Abdominal Imaging: Further Insight into the Natural History of Renal Cell Carcinoma. Journal of Urology, 2012, 188, 1089-1094.	0.4	4
164	Monosomy of Chromosome 9 Is Associated With Higher Grade, Advanced Stage, and Adverse Outcome in Clear-cell Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2020, 18, 56-61.	1.9	4
165	The future of â€œRetroâ€•robotic partial nephrectomy. Translational Andrology and Urology, 2021, 10, 2199-2208.	1.4	4
166	Renal mass biopsy: A strategy to reduce associated costs and morbidity when managing localized renal masses. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 790.e9-790.e15.	1.6	4
167	Predictive Models for Patients with a Renal Mass in the Clinical Trenches Continue to be a Muddy Proposition. European Urology, 2022, , .	1.9	4
168	Understanding Mutational Drivers of Risk: An Important Step Toward Personalized Care for Patients with Renal Cell Carcinoma. European Urology Focus, 2017, 3, 428-429.	3.1	3
169	Reply to Patrick O. Richard, Micheal A.S. Jewett and Antonio Finelli's Letter to the Editor re: Alexander Kutikov, Marc C. Smaldone, Robert G. Uzzo, Miki Haifler, Gennady Bratslavsky, Bradley C. Leibovich. Renal Mass Biopsy: Always, Sometimes, or Never? Eur Urol 2016;70:403â€“6. European Urology, 2017, 71, e47-e48.	1.9	3
170	The correlation between gain of chromosome 8q and survival in patients with clear and papillary renal cell carcinoma. Therapeutic Advances in Urology, 2018, 10, 3-10.	2.0	3
171	Reply to J. Lagro et al and G. Lughezzani et al. Journal of Clinical Oncology, 2010, 28, e301-e301.	1.6	2
172	Meaningful Comparison of Robotics Versus Laparoscopy for Nephron-sparing Surgery: No Contest or No Dice?. European Urology, 2012, 62, 1037-1038.	1.9	2
173	Reply to Vincenzo Ficarra, Vito Palumbo, Afrovita Kunguli and Gianluca Giannarini's Letter to the Editor re: Andrea Minervini, Marco Carini, Robert G. Uzzo, Riccardo Campi, Marc C. Smaldone, Alexander Kutikov. Standardized Reporting of Resection Technique During Nephron-sparing Surgery: The Surfaceâ€“Intermediateâ€“Base Margin Score. Eur Urol 2014;66:803â€“5. European Urology, 2015, 67, e48-e51.	1.9	2
174	MP41-11 RESECTION TECHNIQUES FOR NEPHRON SPARING SURGERY (NSS) VARY: INSIGHTS FROM A PROSPECTIVELY COLLECTED MULTI-INSTITUTIONAL COHORT HARNESSING THE SURFACEâ€“INTERMEDIATEâ€“BASE (S.I.B.) MARGIN SCORE (SIB INTERNATIONAL CONSORTIUM). Journal of Urology, 2016, 195, .	0.4	2
175	Editorial Comment. Urology, 2017, 102, 136-137.	1.0	2
176	Quantification of Urology Related Twitter Traffic Activity through a Standardized List of Social Media Communication Descriptors. Urology Practice, 2017, 4, 349-354.	0.5	2
177	The Alphabet Soup of Modern Nephrometry Systems. European Urology Oncology, 2018, 1, 435-436.	5.4	2
178	962 PATHOLOGIC CONCORDANCE OF SYNCHRONOUS UNILATERAL MULTIFOCAL RENAL MASSES. Journal of Urology, 2011, 185, .	0.4	1
179	The Publication Ranking Score for pediatric urology: Quantifying thought leadership within the subspecialty. Journal of Pediatric Urology, 2013, 9, 1108-1113.	1.1	1
180	Key advances promise progress for kidney cancer patients. Nature Reviews Urology, 2015, 12, 69-70.	3.8	1

#	Article	IF	Citations
181	Harnessing Proteinuria as a Predictor of Postsurgical Outcomes in Kidney Cancer Patients. European Urology Focus, 2016, 2, 623-624.	3.1	1
182	Editorial Comment. Journal of Urology, 2016, 196, 1355-1355.	0.4	1
183	PD27-01 CONTEMPORARY UTILIZATION TRENDS AND SURVIVAL OUTCOMES IN PATIENTS UNDERGOING RADICAL CYSTECTOMY AND BLADDER PRESERVATION THERAPY FOR MUSCLE INVASIVE BLADDER CANCER. Journal of Urology, 2016, 195, .	0.4	1
184	Re: Raj Satkunasivam, Sheaumei Tsai, Sumeet Syan, et al. Robotic Unclamped â€œMinimal-marginâ€•Partial Nephrectomy: Ongoing Refinement of the Anatomic Zero-ischemia Concept. Eur Urol 2015;68:705â€“12. European Urology, 2016, 69, e95-e96.	1.9	1
185	PD52-08 CAN LOOKS DECEIVE? NOT ALL CLINICALLY â€œCYSTICâ€•RENAL MASSES HARBOR INDOLENT BIOLOGY. Journal of Urology, 2017, 197, .	0.4	1
186	Use of administrative data for comparative effectiveness research in the treatment of non-prostate genitourinary malignancies. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 193-212.	1.6	1
187	Perioperative Statin Use and Acute Kidney Injury in Patients Undergoing Partial Nephrectomy. Kidney Cancer, 2018, 2, 47-55.	0.4	1
188	Safety of neoadjuvant chemotherapy in patients with muscleâ€invasive bladder cancer and malignant ureteric obstruction. BJU International, 2021, , .	2.5	1
189	Feasibility and Outcomes of Renal Mass Biopsy for Anatomically Complex Renal Tumors. Urology, 2021, 158, 125-130.	1.0	1
190	Reply by Authors. Journal of Urology, 2020, 203, 503-504.	0.4	1
191	Predictors of Positive Surgical Margins after Robot-Assisted Partial Nephrectomy for Localized Renal Tumors: Insights from a Large Multicenter International Prospective Observational Project (The) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.4	1
192	The Power of Hashtags in Social Media: Lessons Learnt from the Urology Tag Ontology Project. European Urology Focus, 2022, , .	3.1	1
193	Should renal and bladder function be our compass for management of vesicoureteral reflux?. Nature Reviews Urology, 2007, 4, 356-357.	1.4	0
194	Assessing the management of localized kidney cancer. Nature Reviews Urology, 2012, 9, 186-188.	3.8	0
195	Reply to Elias S. Hyams, Jeffrey K. Mullins, and Mohamad E. Allafâ€™s Letter to the Editor re: Alexander Kutikov, Boris Rozenfeld, Brian L. Egleston, et al. Academic Ranking Score: A Publication-Based Reproducible Metric of Thought Leadership in Urology. Eur Urol 2012;61:435â€“9. European Urology, 2012, 62, e19-e20.	1.9	0
196	Active Surveillance of the Small Renal Mass. , 2013, , 167-194.		0
197	Reply. Urology, 2015, 86, 306.	1.0	0
198	Editorial Comment. Urology, 2016, 87, 111-113.	1.0	0

#	Article	IF	Citations
199	Biology is Destiny: A Case of Adrenocortical Carcinoma Diagnosed and Resected at Inception in a Patient Under Close Surveillance for Lung Cancer. Urology Case Reports, 2016, 9, 9-11.	0.3	0
200	Editorial Comment. Journal of Urology, 2018, 199, 639-640.	0.4	0
201	The volume-outcome relationship in kidney cancer: is more really better?. Annals of Translational Medicine, 2019, 7, S336-S336.	1.7	0
202	Imaging-Based Scoring Systems for theÂRiskÂStratification of Renal Tumors. , 2019, , 85-99.		0
203	Surgical Approaches to Early Stage Kidney Cancer. , 2012, , 91-107.		0
204	Objectifying Complexity of Kidney Cancers: Relationships of Tumor Anatomy and Outcomes. , 2013, , 201-209.		0
205	Objectifying Complexity of Kidney Cancers: Relationship of Tumor Anatomy and Outcomes. , 2020, , 185-195.		0
206	Can Renal Mass Biopsy Improve Outcomes? Impact on Clinical Decision-Making. , 2020, , 13-30.		0
207	Pathological and genetic markers improve recurrence prognostication with the University of California Los Angeles Integrated Staging System for patients with clear cell renal cell carcinoma. European Journal of Cancer, 2022, 168, 68-76.	2.8	0